期刊文献+

药物涂层支架的研究进展 被引量:3

Research Progress of the Drug-coated Stents
在线阅读 下载PDF
导出
摘要 冠状动脉内安放支架具有操作简便、疗效明显等特点,但由于支架本身是一种金属异物,可以导致血栓的形成和引起机体的免疫反应。因而术后亚急性血栓形成和再狭窄仍是两大主要并发症。而药物涂层支架属于药物洗脱性聚合物涂层支架,即在金属支架表面涂以某种聚合物,并在此基础上结合一种有治疗作用的药物或抗体,将药物运送到病变部位提高局部药物浓度,达到治疗目的。本文综述了药物涂层支架相关问题的研究进展。 Emplacing a stent in the coronary artery has many characteristics. The installation is easy to do and the stent has evident curative effect. However, it will cause thrombosis and immunoreaction because it is metal. So suhurgent thrombosis and restenosis after surgeries are still two major complications. The drug-coated stent is one kind of the drug-eluting stents, whose metal surface is coated by some polymer that combines with a sort of effective drug or antibody. It can transport the drug or antibody to the localily of pathological changes and there in it improves the local drug concentration. In this paper the research progress of interrelated issues about the drugcoated stent is reviewed.
出处 《生物医学工程学杂志》 EI CAS CSCD 北大核心 2005年第2期389-391,共3页 Journal of Biomedical Engineering
基金 重庆市重点高新技术项目资助 (渝计委技 [2 0 0 2 ] 15 71号 )
  • 相关文献

参考文献15

  • 1Kandzari DE, Tcheng JE, Zidar JP. Coronary artery stents:evaluating new designs for contemporary percutaneous intervention. Catheter Cardiovasc Interv, 2002,56(4):562.
  • 2Tamai H, lgaki K, Kyo E,et al. Initial and 6-month results of biodegradable poly-I-lactic acid coronary stents in humans.Circulation, 2000,102(4) : 399.
  • 3Hong MK, Kornowski R, Bramwell O, et al. Paclitaxelcoated Gianturco-Roubin Ⅱ (GR Ⅱ) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model.Coron Artery Dis, 2001,12(6) : 513.
  • 4Tanabe K, Serruys PW, Grube E, a al.TAXUS Ⅲ Trial:instent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.Circulation, 2003,107(4): 559.
  • 5Hong MK, Mintz GS, Lee CW, et al.Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries:a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial(ASPECT). Circulation, 2003,107(4): 517.
  • 6Whelan DM, Vander Giessen W J, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart, 2000;83(3):338.
  • 7Malik N, Gunn J, Shepherd L, et al. Phosphorylcholine-coated stents in porcine coronary arteries:in vivo assessment of biocompatibility. J Invasive Cardiol,2001,13(3):193.
  • 8vLiistro F, Stankovic G, Di Mario C, et al.First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation,2002,105(16):1883.
  • 9Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eightday efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis, 2002;13(3):183.
  • 10Sousa JE, Costa MA, Sousa AG, el al. Two-year angiographic and intravascular ultrasound follow-up after impact sirolimus-eluting stents in human coronary arteries.Circulation, 2003;107(3):381.

二级参考文献2

共引文献8

同被引文献45

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部